Industry Concerned About Excipient Registration and Data Protection Under FDASIA
This article was originally published in The Gold Sheet
Executive Summary
FDA faces a heavy workload in implementing the supply chain provisions of FDASIA, yet developing a unique facility identifier (UFI) for foreign and domestic establishments will be a priority, as many aspects of the law hinge on having this identifier, said an agency official. In the meantime, there are questions concerning the workability of FDASIA’s excipient registration provision and whether confidential information will be protected when FDA exchanges information with foreign governments during inspections.
You may also be interested in...
User Fee Bill Puts Industry, FDA to Work on Supply Chain Risks
The user fee legislation Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains. The bill directs FDA to inspect based on risk rather than time or location, and to rely on trusted foreign inspectorates, while adding new user fees for generic drugs that will boost funding for further expansion of the agency’s inspectorate.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.